Severity
Moderate
FDA Drug recall · Reported September 29, 2021
CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory.
Direct Rx recalled Zonisamide 100 mg Capsules, 30-count bottles, Packaged and Distributed By: Direct Rx Daws… - a moderate-severity action.
Zonisamide 100 mg Capsules, 30-count bottles, Packaged and Distributed By: Direct Rx Daws… was recalled by Direct Rx in September 29, 2021. Reason: CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory.. Check the official notice for the remedy. Verify recall #D-0829-2021 with the FDA Drug before acting.
The recall
Direct Rx issued this moderate-severity FDA Drug recall-CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory..
Sourced from official FDA Drug enforcement records. Verify recall #D-0829-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0829-2021) was formally reported on September 29, 2021, with the manufacturer initiating the action on September 14, 2021. It is classified under Moderate severity (Class II), with a current status of Terminated. Direct Rx is listed as the recalling firm, operating out of Dawsonville, GA. Federal records list the affected scope as 2 bottles.
The documented reason for this recall is: CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory. Distribution data in the federal record shows the product reached: FL only. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
2 bottles
Related Recalls
6
5 from same agency
Zonisamide 100 mg Capsules, 30-count bottles, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg. For Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 61919-0775-30
CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0829-2021 |
| Date reported | September 29, 2021 |
| Date initiated | September 14, 2021 |
| Recalling firm | Direct Rx |
| Firm location | Dawsonville, GA |
| Affected scope | 2 bottles |
| Distribution | FL only |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 29, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.